[1] 龚建平, 覃修福, 裘法祖. 胃癌根治术中间接淋巴显色剂的选择及其初步临床应用[J]. 中华实验外科杂志, 1992, 9(2): 90-91. [2] 陈晓鹏, 童朝刚, 徐龙帅, 等. 伊立替康耦合亚甲蓝靶向示踪大鼠胃癌淋巴结的研究[J]. 中华实验外科杂志, 2010, 27(4): 126-127. [3] 陈晓鹏, 李涛, 张国政, 等. 刮吸解剖法在进展期胃癌淋巴结清扫术中的应用[J]. 中国现代手术学杂志, 2007, 11(3): 168-170. [4] 孙秀娣, 牧人, 周有尚, 等. 中国胃癌死亡率20年变化情况分析及其发展趋势预测[J]. 中华肿瘤杂志, 2004, 26 (1): 429. [5] Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study [J]. Ann Surg Oncol, 2005, 12(12): 981-987. [6] Saito H, Fukumoto Y, Osaki T, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach [J]. World J Surg, 2006, 30 (10): 1864-1869. [7] Coleman LW, Bronstein IB, Holden JA. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas[J]. Anticancer Res, 2001, 21(2A): 1167-1172. [8] Tsavaris N, Lazaris A, Kosmas C, et al. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy[J]. Cancer Chemother Pharmacol, 2009, 64(2): 391-398. [9] Moulder S, Valkov N, Neuger A, et al. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response[J]. Cancer, 2008, 113(10): 2646-2654. [10] 方青芳. 化疗相关性腹泻的发生机制和治疗策略[J]. 中国临床药理学与治疗学, 2009, 14(3): 351-355. |